Goldman Sachs Group Inc Zymeworks Inc. Transaction History

Goldman Sachs Group Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 May 14, 2024	BUY	$4.82 - $7.7 $5.69 Million - $9.09 Million	1,179,893 New	1,179,893 $6.25 Million
Q2 2022 Aug 15, 2022	BUY	$4.82 - $7.7 $3.18 Million - $5.08 Million	659,457 Added 126.71%	1,179,893 $6.25 Million
Q1 2022 May 16, 2022	SELL	$6.0 - $16.98 $12 Million - $33.9 Million	-1,998,572 Reduced 79.34%	520,436 $3.41 Million
Q4 2021 Feb 14, 2022	BUY	$15.19 - $29.33 $34 Million - $65.7 Million	2,240,800 Added 805.44%	2,519,008 $41.3 Million
Q3 2021 Nov 10, 2021	BUY	$27.35 - $37.28 $7.61 Million - $10.4 Million	278,208 New	278,208 $8.08 Million

296K

Ticker ZYME
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,694,400
Market Cap $885M
Description
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas...

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

Stay updated on Goldman Sachs Group Inc with notifications on news.